Novo Nordisk Surges 25% in 30 Days as Market Rewards AI-Driven R&D Overhaul
Novo Nordisk posted strong Q1 2026 earnings and gained 25% in 30 days after closing its internal cell therapy unit and outsourcing Parkinson's drug development to AI-platform firm Cellular Intelligence. The move reflects a broader pharma pivot: licensing out early-stage risk while concentrating capital on proven GLP-1 franchises. NVIDIA's BioNeMo is emerging as the compute backbone for this shift across the industry.
Salvado•